Cyclacel Pharmaceuticals, Inc.

NasdaqCM:CYCC.P Stock Report

Market Cap: US$2.4m

Cyclacel Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Spiro Rombotis

Chief executive officer

US$661.0k

Total compensation

CEO salary percentage84.7%
CEO tenure26.8yrs
CEO ownership2.1%
Management average tenureno data
Board average tenure7.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Spiro Rombotis's remuneration changed compared to Cyclacel Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$20m

Dec 31 2023US$661kUS$560k

-US$23m

Sep 30 2023n/an/a

-US$25m

Jun 30 2023n/an/a

-US$24m

Mar 31 2023n/an/a

-US$23m

Dec 31 2022US$764kUS$546k

-US$21m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$20m

Dec 31 2021US$1mUS$531k

-US$19m

Sep 30 2021n/an/a

-US$20m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$1mUS$531k

-US$12m

Sep 30 2020n/an/a

-US$8m

Jun 30 2020n/an/a

-US$8m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$1mUS$531k

-US$8m

Sep 30 2019n/an/a

-US$8m

Jun 30 2019n/an/a

-US$8m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$753kUS$531k

-US$7m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$14m

Mar 31 2018n/an/a

-US$15m

Dec 31 2017US$776kUS$531k

-US$15m

Compensation vs Market: Spiro's total compensation ($USD661.05K) is about average for companies of similar size in the US market ($USD680.27K).

Compensation vs Earnings: Spiro's compensation has been consistent with company performance over the past year.

CEO

Spiro Rombotis (65 yo)

26.8yrs

Tenure

US$661,049

Compensation

Mr. Spiro George Rombotis has been President of Cyclacel Pharmaceuticals Inc. (formerly, Cyclacel Pharmaceuticals, Inc. (formerly known as Cyclacel Group plc)) since August 1997 and has been its Founding C...

Board Members

NamePositionTenureCompensationOwnership
Spiro Rombotis
President18.3yrsUS$661.05k2.05%
$ 48.6k
Paul McBarron
Executive VP of Finance18.3yrsUS$352.62k1.11%
$ 26.3k
Brian Schwartz
Chief Medical Officer & Director3.5yrsUS$84.49k1.14%
$ 27.1k
Samuel Barker
Independent Director9.8yrsUS$97.99k0.28%
$ 6.7k
Christopher Henney
Independent Chairman18.3yrsUS$136.99k0.28%
$ 6.6k
Karin Walker
Independent Director3.6yrsUS$95.49k0.29%
$ 6.8k
Edward Sikora
Member of Scientific Advisory Boardno datano datano data
Michel Marty
Member of Scientific Advisory Boardno datano datano data
Kenneth Harrap
Member of Scientific Advisory Boardno datano datano data
Stanley Kaye
Member of Scientific Advisory Boardno datano datano data
Robert Jay Spiegel
Independent Vice Chairman5.8yrsUS$115.99k0.28%
$ 6.6k
Kenneth Ferguson
Independent Director2yrsUS$85.49k0.26%
$ 6.3k

7.8yrs

Average Tenure

68yo

Average Age

Experienced Board: CYCC.P's board of directors are considered experienced (7.8 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.